Search Result

Results for "

H22

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AMPK (1) Apoptosis (5) Atg7 (1) Autophagy (1) Bacterial (1) Bcl-2 Family (2) c-Met/HGFR (1) Caspase (2) CDK (1) CTLA-4 (1) DNA/RNA Synthesis (1) ERK (1) FAK (1) Fungal (1) HDAC (1) IFNAR (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Interleukin Related (2) JAK (1) MEK (1) Mitochondrial Metabolism (1) MOFs (5) PARP (1) Pim (1) PROTACs (1) Proteasome (1) Raf (1) Ras (1) Reactive Oxygen Species (ROS) (2) STAT (1) TGF-β Receptor (1) VEGFR (1)
By Research Areas:	Cancer (13) Cardiovascular Disease (1) Endocrinology (1) Infection (2) Inflammation/Immunology (5)

By Targets:

AMPK (1)

Apoptosis (5)

Atg7 (1)

Autophagy (1)

Bacterial (1)

Bcl-2 Family (2)

c-Met/HGFR (1)

Caspase (2)

CDK (1)

CTLA-4 (1)

DNA/RNA Synthesis (1)

ERK (1)

FAK (1)

Fungal (1)

HDAC (1)

IFNAR (1)

Indoleamine 2,3-Dioxygenase (IDO) (1)

Interleukin Related (2)

JAK (1)

MEK (1)

Mitochondrial Metabolism (1)

MOFs (5)

PARP (1)

Pim (1)

PROTACs (1)

Proteasome (1)

Raf (1)

Ras (1)

Reactive Oxygen Species (ROS) (2)

STAT (1)

TGF-β Receptor (1)

VEGFR (1)

By Research Areas:

Cancer (13)

Cardiovascular Disease (1)

Endocrinology (1)

Infection (2)

Inflammation/Immunology (5)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99136

*Anti-Mouse IFN gamma Antibody (H22)* 1 Publications Verification	IFNAR	Infection Inflammation/Immunology
Anti-Mouse IFN gamma Antibody (H22) is an anti-mouse IFN gamma IgG antibody inhibitor derived from host Armenian Hamster. Anti-Mouse IFN gamma Antibody (H22) abrogates specific binding of ^I25II-rIFN-γ to macrophages. Anti-Mouse IFN gamma Antibody (H22) inhibits macrophage-activating factor (MAF) (ID₅₀ = 56 ng). Anti-Mouse IFN gamma Antibody (H22) inhibits IFN-gamma dependent antiviral activity (ID₅₀ = 2 ng). Anti-Mouse IFN gamma Antibody (H22) neutralizes IFNγ in mice. Anti-Mouse IFN gamma Antibody (H22) can be used for the researches of inflammation and infection, such as arthritis .

HY-108551

MG-262 1 Publications Verification Z-Leu-Leu-LeuB(OH)2; ZL3B	Proteasome VEGFR Apoptosis Reactive Oxygen Species (ROS)	Cardiovascular Disease Inflammation/Immunology Cancer
MG-262 (Z-Leu-Leu-LeuB(OH)2; ZL3B) is a reversible proteasome inhibitor. MG-262 down-regulates VEGF receptor Flt-1. MG-262 inhibits cell growth and induces apoptosis in malignant cells. MG-262 induces reactive oxygen species (ROS). MG-262 can be used for anti-cancer study .

HY-151425

TDO-IN-1	Indoleamine 2,3-Dioxygenase (IDO)	Cancer
TDO-IN-1 is an orally active and selective inhibitor of tryptophan 2,3-dioxygenase (TDO), shows excellent selectivity over indoleamine-2,3-dioxygenase (IDO), with an IC₅₀ value of 0.62 μM (IDO). TDO-IN-1 reverse the local immune tolerance of tumor tissue to inhibit tumor growth in vivo .

HY-161141

EGFR/c-Met-IN-2	c-Met/HGFR	Cancer
EGFR/ C-Met-in-2 (Compound H-22) is a dual inhibitor of EGFR/c-Met. EGFR/c-Met-IN-2 inhibits cell proliferation by arresting G2/M phase. EGFR/c-Met-IN-2 has antitumor activity .

HY-172108

TGFβRI-IN-7	TGF-β Receptor	Cancer
TGFβRI-IN-7 (compound 16W) is a potent inhibitor of TGFβRI. TGFβRI-IN-7 inhibits SMAD2/3 phosphorylation and H22 cell viability with IC₅₀ values of 12 and 65 nM, respectively. TGFβRI-IN-7 shows anti-tumor efficacy in a xenograft model of H22 cells, with TGI of 79.6 % .

HY-W040584

1H,1'H-2,2'-Biimidazole	MOFs	Others
1H,1'H-2,2'-Biimidazole is a metal-organic framework (MOF).

HY-126876

GL-V9 1 Publications Verification	Apoptosis AMPK Reactive Oxygen Species (ROS)	Cancer
GL-V9 inhibits proliferation of HepG2 cell (IC₅₀ is 35.2 μM) through induction of apoptosis and cell cycle arrest at G2/M phase. GL-V9 regulates mitochondrial membrane potential and increases the production of intracellular reactive oxygen species. GL-V9 inhibits the pentose phosphate pathway (PPP), enhances fatty acid oxidation (FAO) through activation of AMPK, and thus inhibits the metastasis of cancer cells. GL-V9 exhibits antitumor efficacy in mouse model .

HY-144232

Anticancer agent 28	Others	Cancer
Anticancer agent 28 shows good antitumor activity in H22 allogeneic mice in vivo. Anticancer agent 28 has inhibitory potency in K562 cells of 50 times than oridonin, and its IC₅₀ value is 0.09 μM.

HY-175459

PROTAC FAK degrader 3	PROTACs FAK	Inflammation/Immunology Cancer
PROTAC FAK degrader 3 is a selective FAK PROTAC degrader (DC₅₀ = 1.08 nM). PROTAC FAK degrader 3 induces FAK degradation dependent on the ubiquitin-proteasome system and its binding to FAK and CRBN. PROTAC FAK degrader 3 upregulates MHC-I gene transcription and tumor cell surface expression by inhibiting the non-catalytic activity of FAK, leading to increased antigen presentation and activation of cytotoxic CD8 T cells. PROTAC FAK degrader 3 enhances in vivo anti-tumor activity by promoting MHC-I expression and enhancing T cell activation. PROTAC FAK degrader 3 can be used in cancer research targeting FAK degradation in ovarian cancer, hepatocellular carcinoma, and other cancers. (Pink: FAK-IN-3:HY-143407, Blue: Thalidomide-4-OH:HY-103596, Blue + Black: FAK ligand-3: HY-W939883, Black: Linker) .

HY-139815

ZYJ-34c	HDAC	Cancer
ZYJ-34c is an orally active and potent histone deacetylase inhibitor (HDACi) with IC₅₀s of 0.056 μM and 0.146 μM for HDAC6 and HDAC8, respectively. ZYJ-34c causes G1 phase arrest in low concentration. ZYJ-34c has antiproliferative activities. ZYJ-34c exhibits antitumor potency in MDA-MB-231 and HCT116 xenograft models and possesses antimetastatic potential in a mouse hepatoma-22 (H22) pulmonary metastasis model .

HY-N13352

Bufothionine	Mitochondrial Metabolism STAT JAK Interleukin Related Atg7 Autophagy Pim	Inflammation/Immunology Cancer
Bufothionine is an alkaloid. Bufothionine can be isolated from Cinobufacini. Bufothionine induces mitochondria-mediated Apoptosis. Bufothionine significantly reduces serum IL-6 concentration, suppresses p-Stat3 ^tyr705, p-Stat3 ^ser727 and Jak2 expressions. Bufothionine upregulates Atg5, Atg7 and LC3Ⅱ expressions. Bufothionine induces Autophagy. Bufothionine suppresses PIM3 expression. Bufothionine relieves symptoms of H22-tumor-bearing mice and exerts anti-inflammation activity. Bufothionine exerts anti-cancer activities against gastric cancer .

HY-182447

Contragestazol DL111-IT	CDK Apoptosis	Endocrinology Cancer
Contragestazol (DL111-IT) is a non-hormonal antifertility agent. Contragestazol reduces the expression of Cyclin D1 and CDK4, increases the expression of total retinoblastoma protein (pRb), and decreases the level of hyperphosphorylated pRb. Contragestazol induces G₀/G₁ phase cell cycle arrest. Contragestazol inhibits embryonic development by inducing luteal cell apoptosis and reducing intrauterine polyamine levels. Contragestazol exhibits antitumor activity against prostate cancer, S180 tumor and H22 tumor. Contragestazol shows extremely potent activity in terminating early pregnancy in animals .

HY-P10832

ATWLPPRAANLLMAAS	Apoptosis Ras Raf MEK ERK Caspase PARP Bcl-2 Family	Cancer
ATWLPPRAANLLMAAS is a chimeric peptide with anti-angiogenic and potent anti-tumor effects. ATWLPPRAANLLMAAS can inhibit the proliferation, viability, migration, and invasion of human hepatocellular carcinoma cells, and induce apoptosis. .

HY-W128191

1H,1'H-2,2'-Bipyrrole 2,2'-Bipyrrole	MOFs	Others
1H,1'H-2,2'-Bipyrrole (2,2'-Bipyrrole) is a metal-organic framework (MOF).

HY-W456336

4,4'-(1H,1'H-[2,2'-Biimidazole]-1,1'-diyl)dibenzoic acid	MOFs	Others
4,4'-(1H,1'H-[2,2'-Biimidazole]-1,1'-diyl)dibenzoic acid is a metal-organic framework (MOF).

HY-W075088

1,1'-Diethyl-1H,1'H-2,2'-biimidazole 1,1'-Diaethyl-2,2'-biimidazol	MOFs	Others
1,1'-Diethyl-1H,1'H-2,2'-biimidazole (1,1'-Diaethyl-2,2'-biimidazol) is a metal-organic framework (MOF).

HY-W112832

1,1'-Bis(pyridin-4-ylmethyl)-1H,1'h-2,2'-biimidazole 1,1-Bis(pyridin-4-ylmethyl)-2,2-bisimidazole	MOFs	Others
1,1'-Bis(pyridin-4-ylmethyl)-1H,1'h-2,2'-biimidazole (1,1-Bis(pyridin-4-ylmethyl)-2,2-bisimidazole) is a metal-organic framework (MOF).

HY-P991960

JS007	CTLA-4 Interleukin Related	Cancer
JS007 is a humanized IgG1 monoclonal antibody and also a CTLA-4 binder, with a K_d of 0.21 nM for CTLA-4. JS007 blocks the interaction between CTLA-4 and B7-1. JS007 activates T cells, promotes increased IL-2 secretion, and inhibits tumor growth in CTLA-4 knock-in mouse syngeneic tumor models. JS007 is applicable to research related to cancer and advanced solid tumors.

HY-N17440

2-Methoxyjuglone	Apoptosis Caspase Bcl-2 Family DNA/RNA Synthesis Bacterial Fungal	Infection Inflammation/Immunology Cancer
2-Methoxyjuglone, a naphthoquinone, is an apoptosis inducer. 2-Methoxyjuglone activates caspase-9 and caspase-3 via the mitochondrial cytochrome c-dependent intrinsic apoptosis cascade. 2-Methoxyjuglone increases pro-apoptotic Bax levels, decreases anti-apoptotic Bcl-2 levels, and promotes mitochondrial cytochrome c release. 2-Methoxyjuglone induces apoptosis morphological features, early apoptosis, S-phase and G₂/M-phase cell cycle arrest, and DNA double-strand breaks. 2-Methoxyjuglone exerts activity against Gram-positive bacteria, pathogenic fungi, and phytopathogenic fungi. 2-Methoxyjuglone can be used for the research of hepatocellular carcinoma, osteosarcoma, colon adenocarcinoma, breast cancer, fungal infection, bacterial infection .

Cat. No.	Product Name	Target	Research Area